肝细胞生长因子和骨形态发生蛋白在心血管疾病中的应用

doi:10.3760/cma.j.issn.1007-1245.2022.04.036

摘要/Abstract

摘要： 肝细胞生长因子是一种多效的间充质因子，具有多种生物学活性，对细胞的生长、运动和形态具有调节作用，可促进血管生成，并抗纤维化和抑制细胞凋亡，对心血管细胞有重要的保护作用。骨形态发生蛋白是转化生长因子-β超家族的一员，近年来，关于骨形态发生蛋白与心血管疾病形成之间的研究越来越多，不同骨形态发生蛋白分型在机体各组织和器官中分布差异显著，且骨形态发生蛋白在血管动脉钙化、血管炎症和动脉粥样硬化等病理形成过程中发挥一定作用。因此，对肝细胞因子和骨形态发生蛋白的深入研究，可为临床心血管疾病的预防和诊治提供一条新思路，本研究从肝细胞生长因子和骨形态发生蛋白对心血管疾病的应用进行总结。

关键词: 肝细胞生长因子, 骨形态发生蛋白, 心血管疾病

Abstract: Hepatocyte growth factor is a multi-effect mesenchymal factor with various biological activities, which can regulate the growth, movement, and morphology of cells, promote the angiogenesis, resist the fibrosis, and inhibit the apoptosis, and plays an important role in protecting cardiovascular cells. Bone morphogenetic protein (BMP) is a member of transforming growth factor-β superfamily. In recent years, there have been more and more researches on the relationship between BMP and cardiovascular disease formation. Different types of BMP are significantly differently distributed in various tissues and organs of the body, and BMP plays a certain role in the pathological formation of vascular artery calcification, vascular inflammation, and atherosclerosis. Therefore, the in-depth study on hepatocyte growth factor and BMP can provide a new idea for the prevention, diagnosis, and treatment of clinical cardiovascular diseases. This study summarizes the application of hepatocyte growth factor and BMP in cardiovascular diseases.

Key words: Hepatocyte growth factor, Bone morphogenetic protein, Cardiovascular diseases

付林, 刁树玲. 肝细胞生长因子和骨形态发生蛋白在心血管疾病中的应用[J]. 国际医药卫生导报, 2022, 28(4): 589-592.

Fu Lin, Diao Shuling. Application of hepatocyte growth factor and bone morphogenetic protein in cardiovascular diseases[J]. International Medicine and Health Guidance News, 2022, 28(4): 589-592.

参考文献

[1] 赵智明,张静,张蓓蓓,等. 法舒地尔对压力超负荷大鼠心肌肝细胞生长因子表达的影响[J]. 国际心血管病杂志,2017,44(1):30-33,42. DOI:10.3969/j.issn.1673-6583.2017. 01.008.

[2] 高怡加,黄培镇,李悦,等. 骨碎补总黄酮对牵张成骨过程中骨形态发生蛋白-2和转化生长因子-β1表达的影响[J]. 广州中医药大学学报,2016,33(5):679-683. DOI:10.13359/j.cnki.gzxbtcm.2016.05.015.

[3] 高安琪,于丹丹,张之然,等. 骨形态发生蛋白参与心血管疾病形成的机制探讨[J]. 中国循环杂志,2016,31(11):1139-1141. DOI:10.3969/j.issn.1000-3614.2016.11.022.

[4] Cheng Z, Liu L, Zhang XJ, et al. Peroxisome Proliferator-Activated Receptor gamma negatively regulates liver regeneration after partial hepatectomy via the HGF/c-Met/ERK1/2 pathways[J]. Sci Rep, 2018, 8(1): 11894. DOI: 10.1038/s41598-018-30426-5.

[5] 罗进勇. 骨形态发生蛋白9促成骨的分子机制[J]. 重庆医学, 2016, 45(9): 1153-1155,1162. DOI:10.3969/j.issn.1671-8348.2016.09.001.

[6] Chen QY, Jiao DM, Wu YQ, et al. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway[J]. Oncotarget, 2016, 7(14): 18247-18261. DOI: 10.18632/oncotarget.7570.

[7] 郭义威,陶晶,王志勇. miR-425-5p通过调控靶基因HGF促进急性心肌梗死诱导心肌纤维化的分析[J]. 临床与实验病理学杂志,2019,35(4):425-429. DOI:10.13315/j.cnki.cjcep.2019.04.011.

[8] 罗姝,刘世平,龚君佐,等. HGF及血清炎症因子的变化与CAS严重程度的相关性分析[J]. 基因组学与应用生物学,2018,37(11):4878-4883. DOI:10.13417/j.gab.037. 004878.

[9] 张亮,胡泽平,圣波,等. 肝细胞生长因子对动脉粥样硬化模型兔巨噬细胞M1、M2亚型及斑块成分的影响[J]. 安徽医科大学学报,2017,52(4):484-490. DOI:10.19405/j.cnki.issn1000-1492.2017.04.005.

[10] 金鹏,李伟,李涛,等. 高血压患者血清肝细胞生长因子的表达及与血管内皮功能的关系[J]. 中国当代医药,2016,23(30):143-145.

[11] 周锐. 高血压患者血清肝细胞生长因子的表达及与血管内皮功能的关系[J]. 中国老年学杂志,2017,37(9):2181-2182. DOI:10.3969/j.issn.1005-9202.2017.09.044.

[12] 付芳芳,郝斌,杨涛,等. HGF对腔内治疗术后血管再狭窄的防治作用[J]. 中国医学创新,2010,7(8):153-154. DOI:10.3969/j.issn.1674-4985.2010.08.083.

[13] 刘铁成(综述),刘恩照(审校). 心房利钠肽和转化生长因子β1在心房颤动心房纤维化进程中的作用及相互联系[J]. 中国循环杂志,2016,31(3):298-300. DOI:10.3969/j.issn.1000-3614.2016.03.022.

[14] Saren G, Yi X, Gong Y. Pleiotropic effects and biological activities of atorvastatin: the sun never set[J]. Int J Cardiol, 2018 , 254:261. DOI: 10.1016/j.ijcard.2017. 06.097.

[15] Taniyama Y, Morishita R, Aoki M, et al. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy[J]. Hypertension. 2002, 40(1): 47-53. DOI: 10.1161/01.hyp.0000020755.56955.bf.

[16] Sun M, Chang Q, Xin M, et al. Endogenous bone morphogenetic protein 2 plays a role in vascular smooth muscle cell calcification induced by interleukin 6 in vitro[J]. Int J Immunopathol Pharmacol, 2017, 30(3): 227-237. DOI: 10.1177/0394632016689571.

[17] 陈若诗,王志维. 骨形态发生蛋白在心脏和血管疾病发生发展中的作用[J]. 中国心血管病研究,2019,17(11):1037-1041. DOI:10.3969/j.issn.1672-5301.2019.11.017.

[18] 李波,李晓阳,仲威,等. CD137-CD137 L 信号通路通过调控小鼠血管平滑肌细胞自噬小体出胞影响动脉粥样硬化钙化形成[J]. 中华心血管病杂志,2017,45(1):49-56. DOI:10.3760/cma.j.issn.0253-3758.2017.01.010.

[19] 魏晓. 骨形态发生蛋白4与血管钙化的相关性[J]. 中国动脉硬化杂志,2016,24(5):529-532.

[20] 杨萍,崔星钢,李波,等.1,25-(OH)2D3通过Ca2+/CaM信号调控内皮细胞自噬抑制动脉粥样硬化钙化[J].中国动脉硬化杂志,2018,26(11):1091-1098. DOI:10.3969/j.issn.1007-3949.2018.11.004

[21] 赵欣,韦清霞,杨隽. 骨形态形成蛋白信号在内皮生理及肺动脉高压中的调控机制[J]. 协和医学杂志,2020,11(6):720-726. DOI:10.3969/j.issn.1674-9081.2020.06.015.

[22] King T, de Caestecker M, Lowery JW. Reply to "Bone morphogenetic protein's contribution to pulmonary artery hypertension"[J]. Surg Neurol Int, 2016, 7:91. DOI: 10.4103/2152-7806.192635.

[23] 覃春美,吴蔚桦,刘建,等. 骨形态生成蛋白2信号通路介导的肾动脉钙化对糖尿病肾病进展的影响[J]. 中华肾脏病杂志,2016,32(3):173-179. DOI:10.3760/cma.j.issn.1001- 7097.2016.03.003.

[24] 姚小兵. 肾纤维化的发病机制及治疗研究进展[J]. 国际泌尿系统杂志,2019,39(2):371-374. DOI:10.3760/cma.j.issn.1673-4416.2019.02.055.

[25] Chen X, Xu J, Jiang B, et al. Bone morphogenetic protein-7 antagonizes myocardial fibrosis induced by atrial fibrillation by restraining transforming growth factor-β (TGF-β)/Smads signaling[J]. Med Sci Monit, 2016, 22: 3457-3468. DOI: 10.12659/msm.897560.